Novodiag assay will enable rapid detection of novel coronavirus and influenzas. Credit: Mobidiag Ltd

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Finnish company Mobidiag has initiated the development of Novodiag molecular diagnostic test to enable swift diagnosis of the new coronavirus 2019-nCoV and other influenza viruses.

Chinese clinical diagnostics company Autobio Diagnostics and Automobi Molecular Diagnostics, a joint venture (JV) firm of Mobidiag and Autobio, are also part of the initiative.

Novodiag assay will leverage a fully automated ‘sample-in, result-out’ system to the viruses simultaneously in around 30 minutes.

The platform, operated without the need for highly trained personnel, enables delivery to high-risk locations suffering from healthcare staff crisis.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mobidiag CEO Tuomas Tenkanen said: “It is vital that molecular diagnostics solutions be utilised to fight back against novel coronavirus which has emerged as a significant threat to health across the world.

“Our new Novodiag assay will uniquely offer rapid and fully automated molecular profiling to simultaneously detect novel coronavirus and common influenza strains and guide clinicians more quickly towards moving patients to efficient isolation measures and make better-informed treatment decisions, in situations where time is critical.”

Earlier this week, the UK launched a coronavirus diagnostic test to strengthen its testing capabilities. The launch will help in equipping 12 laboratories to test coronavirus.

Co-Diagnostics and Novacyt’s division Primerdesign also launched research use only (RUO) tests for coronavirus. Subsequently, Co-Diagnostics announced sales of its screening test to various international markets.

Meanwhile, the coronavirus outbreak death toll crossed one thousand, with confirmed cases rising to around 43,000.